Who is sponsoring CyFluCyATG?

CyFluCyATG is sponsored by Cooperative Study Group A for Hematology.

What condition does CyFluCyATG study?

CyFluCyATG studies Bone Marrow Failure Syndromes.

What drugs are being tested in CyFluCyATG?

Interventions: Cyclophosphamide-fludarabine-anti thymocyte globulin.

What is the status of CyFluCyATG?

CyFluCyATG is currently COMPLETED.

Last reviewed 2011-02-16 · How we verify

Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome (CyFluCyATG)

NCT00774527 Phase 3 COMPLETED

Randomized comparison of cyclophosphamide versus reduced-dose cyclophosphamide plus fludarabine in addition to anti-thymocyte globulin for the conditioning therapy in allogeneic hematopoietic cell transplantation for bone marrow failure syndrome.

Details

Lead sponsor	Cooperative Study Group A for Hematology
Phase	Phase 3
Status	COMPLETED
Enrolment	82
Start date	2003-03
Completion	2011-01

Conditions

Bone Marrow Failure Syndromes

Interventions

Cyclophosphamide-fludarabine-anti thymocyte globulin

Primary outcomes

Occurrence of regimen related toxicities — 7 years
1.1 Compare the regimen related toxicities of two different conditioning regimens, cyclophosphamide (Cy)+anti-thymocyte globulin (ATG) (Cy-ATG) vs. reduced dose of Cy+fludarabine (Flu)+ATG (Cy-Flu-ATG) after allogeneic hematopoietic cell transplantation (allo-HCT).

Countries

South Korea